Before proceeding to ELELYSO.com please scroll to review Important Safety Information and Indication. Click the X in the upper right-hand corner to close this box.
As with any intravenous protein medicine, like enzyme replacement therapy (ERT), severe allergic reactions (including anaphylaxis) have been observed in patients treated with ELELYSO. If this occurs, ELELYSO should be immediately discontinued, and appropriate medical treatment should be initiated. Patients who have experienced anaphylaxis to ELELYSO or another ERT should proceed with caution upon retreatment.
In addition, infusion reactions (including allergic reactions)—defined as a reaction occurring within 24 hours of the infusion—were the most commonly observed reactions to ELELYSO. The most commonly observed infusion reactions were headache, chest pain or discomfort, weakness, fatigue, hives, abnormal redness of the skin, increased blood pressure, back or joint pain, and flushing. Other infusion or allergic reactions included swelling of the face, mouth, and/or throat; wheezing; shortness of breath; skin color turning blue; coughing; and low blood pressure. Most of these reactions were mild and did not require treatment.
Management of infusion reactions is based on the type and severity of the reaction. Your doctor may manage infusion reactions by temporarily stopping the infusion, slowing the infusion rate, or treating with medications such as an antihistamine and/or a fever reducer. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions.
Other common adverse reactions observed were upper respiratory tract infections, throat infection, flu, urinary tract infection, and pain in extremities.
As with all therapeutic proteins, including ERTs, there is a possibility of developing antibodies to ELELYSO. However, it is currently unclear whether this has an impact on the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to ELELYSO should continue to be monitored for antibodies. Comparison of the frequency of antibodies across ERTs may be misleading. Patients who have developed infusion or immune reactions with ELELYSO or with another ERT should be monitored for antidrug antibodies when being treated with ELELYSO.
If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks.
ELELYSO™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.
Pfizer–Committed to Discovering New Therapies for Rare Diseases
As one of the world's largest research-based pharmaceutical companies, Pfizer is committed to helping address the unmet medical needs of people with rare diseases. Pfizer partners with advocacy groups, academic organizations, and biopharmaceutical companies to discover, develop, and deliver new treatments and support programs for rare diseases.
In 2009, Pfizer and Protalix Biotherapeutics entered into an agreement to further develop and bring ELELYSO™ (taliglucerase alfa) for injection to the United States. This agreement is just one way each company has demonstrated their commitment to the rare disease community, including Gaucher disease.
Protalix–A Personal Connection to Gaucher Disease
Even though Gaucher disease is a rare disease, it is very familiar to the employees of Protalix, an Israeli-based biotech company. Many have family members and friends who have personal experience with Gaucher disease so the employees truly understand the impact it can have on patients and their families. Out of their passion to improve these patients lives, ELELYSO was developed as a treatment for Type 1 Gaucher disease.
A Pfizer Patient Affairs Liaison is available to help provide a high level of support for patients. Patients and their family members can call with general questions about Pfizer, feedback about service provided by the Gaucher Personal Support program, and assistance with finding additional Gaucher-related resources.
The Patient Affairs Liaison will:
You can contact your Patient Affairs Liaison, Mariah K., RN, at: GaucherPatientAffairs@pfizer.com.